Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029208 · ClinicalTrials.gov registry record · Phase 3
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
NCT03029208 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 312 participants.
The verdict
NCT03029208, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
Study Summary
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
Interventions
- DRUG Darbepoetin alfa
- DRUG Daprodustat
- DRUG Iron therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2020-09-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03029208
The ClinicalTrials.gov registry entry for NCT03029208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Darbepoetin alfa is the first listed.
NCT03029208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03029208 about?
NCT03029208 is a clinical study titled "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)". The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.
What is the current status of trial NCT03029208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2017-05-11. Estimated completion is 2020-09-24.
What interventions are being tested in trial NCT03029208?
The interventions under investigation include: Darbepoetin alfa (DRUG), Daprodustat (DRUG), Iron therapy (DRUG).
Who is sponsoring clinical trial NCT03029208?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.